AGP Picks
View all

The most trusted news from Latin America

Provided by AGP

Good Morning! Latin America: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Good Morning! Latin America.

Press releases published on April 16, 2026

Plato Gold Corp. Announces the Closing of the Sale of Timmins-Area Properties to Mayfair Gold Corp.
Elcora Reports High-Grade Vanadium-Lead Mineralisation from surface samples in Morocco, Advancing Downstream Strategy in a Critical-Mineral Market
Remedy Plan Therapeutics Announces Multiple Presentations at the AACR Annual Meeting 2026
Fredonia Mining Inc. Commences 10,000 Metre Drill Program at El Dorado-Monserrat Project
Transocean Ltd. Announces $158 Million Award for Ultra-Deepwater Drillship
Bitget lanza el Broker Max Check Program con hasta 12.000 USDT para nuevos brokers
Bitget lance le programme Broker Max Check avec jusqu’à 12 000 USDT pour les nouveaux courtiers
ביטגט משיקה את תוכנית Broker Max Check עם עד 12,000 USDT עבור ברוקרים חדשים
ビットゲット、新規ブローカー向けに最大12,000 USDTの「ブローカー・マックス・チェック・プログラム」を開始
Bitget, 신규 브로커 대상 최대 1만2,000 USDT 제공 ‘Broker Max Check Program’ 출시
Bitget Lancarkan Program Broker Max Check Dengan Ganjaran Sehingga 12,000 USDT untuk Broker Baharu
Bitget Lança Programa Broker Max Check que Oferece até 12.000 USDT para Novas Corretoras
Bitget 推出经纪商“顶格赏金”计划,新经纪商最高可获 12,000 USDT 奖励
Bitget 推出經紀商頂格賞金計劃,新經紀商可獲高達 12,000 USDT 獎勵
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Titan Extends Kilbourne Graphite Mineralization,  Advances Germanium and the 2026 Multi-Commodity Exploration Strategy
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

Share us

on your social networks:

Sign up for:

Good Morning! Latin America

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.